Drug Price Negotiations & Rebates

Return to Policy & Issues

The pandemic is having a devastating impact on America’s seniors. The Medicare Part D prescription drug program provides our nation’s seniors with affordable drug coverage, which is more important now than ever. However, the Administration would threaten to destabilize the Medicare Part D program by dramatically increasing premiums for the vast majority of Part D enrollees.

The White House should abandon the Executive Order on rebates that would gut tools used for negotiating lower drug costs.

Read PCMA Statement on Executive Order

“The president is deeply committed to protecting America’s seniors,” Azar said. “He does not want any risk that any action could cause seniors’ premiums to increase.”

– Alex Azar, Health and Human Services Secretary
(Politico)

 

Why now, during a pandemic and economic downturn, and right before an election, would the White House add costs to seniors and taxpayers?

The Administration is gutting tools for negotiating lower drug prices.

  • Medicare drug premiums could increase 25%

  • Taxpayer costs could increase up to $400 billion

PCMA Infographic - Premium Impact of Disallowing Rebates in Medicare Part D

“Simply trying to eliminate rebating without any other steps threatens to drive up drug prices overall…Rebates are a key mechanism that insurers use to try to reduce net drug prices.”

– Aaron Kesselheim, Associate Professor of Medicine, Harvard Medical School
(Read more quotes: Coalition for Affordable Prescription Drugs)

 

INFOGRAPHICS:

“I have never seen a regulatory impact statement on a proposed rule state so clearly that the impacts are impossible to know and that the best analyses suggest some very negative results such as higher premiums in Medicare Part D and overall higher drug costs.”

– Ian Spatz, Senior Advisor, Manatt Health
(Read more quotes: Coalition for Affordable Prescription Drugs)

 

‘‘The concern remains that this move fails to address the root cause of high prescription drug costs which starts with list prices set by drug manufacturers…The proposed rule risks destabilizing Part D premiums for seniors.”

– Allyson Y. Schwartz, CEO, Better Medicare Alliance
(Read more quotes: Coalition for Affordable Prescription Drugs)

 

Research

See All Research

OP-Eds & Press Releases

OP-Eds

See All Highlights

Press Releases

See All Press Releases